{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-26-000004","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.402671+00:00","generated_at":"2026-05-16T04:54:44.937638+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie Q4 revenue $16.6B (+10%); FY2025 adj EPS $10.00; guides FY2026 adj EPS $14.37-$14.57","bullets":["FY2025 revenue $61.160B (+8.6% reported); GAAP diluted EPS $2.36; adjusted diluted EPS $10.00 (-1.2% YoY).","Q4 revenue $16.618B (+10% reported); GAAP EPS $1.02; adjusted EPS $2.71; includes $0.71 IPR&D hit.","Immunology portfolio grew 14% in FY2025; Skyrizi $17.562B, Rinvoq $8.304B; Humira fell to $4.540B.","FY2026 adjusted EPS guidance $14.37-$14.57, excluding future IPR&D and milestones expense.","Announced voluntary pricing agreement with Trump admin; $100B U.S. R&D/capex over 10 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-26-000004","json":"https://secwatch.observer/filing/0001551152-26-000004.json","markdown":"https://secwatch.observer/filing/0001551152-26-000004.md","text":"https://secwatch.observer/filing/0001551152-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/0001551152-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20260204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:54:44.937638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}